Patient perceptions on lipoprotein(a) testing and treatment for secondary prevention of cardiovascular disease: results from the INTERASPIRE study in seven countries across five World Health Organization regions

Health professionals working in CVD care should be aware of the need to investigate patients with coronary disease for Lp(a) and be equipped to give advice on how to reduce overall cardiovascular risk especially given the absence of licenced therapies to treat Lp(a).